General Information


We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of product candidates, validated by human genetics, which we believe will improve the probability of technical success over shorter development timelines.

Employees: 78
Founded: 2013
Contact Information
Address 151 Oyster Point Boulevard, Suite 300, South San Francisco, CA 94080, US
Phone Number 415-231-5660
Web Address
View Prospectus: Alector
Financial Information
Market Cap $1298.9mil
Revenues $21.6 mil (last 12 months)
Net Income $-44.7 mil (last 12 months)
IPO Profile
Symbol ALEC
Exchange NASDAQ
Shares (millions): 9.3
Price range $19.00 - $19.00
Est. $ Volume $175.8 mil
Manager / Joint Managers Morgan Stanley/ BofA Merrill Lynch/ Cowen/ Barclays
CO-Managers -
Expected To Trade: 2/7/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change